EUVIMEDEUVIMED entdecken
Vergleichsstudie

Bridging With Chimeric Antigen Receptor T‐Cell Therapy or Chemotherapy to Allo‐ HSCT in B‐ ALL : A Comparison of Treatment Complications and Survival

Ning Wu, Jun Kong, Meng Lv, Xiao-Dong Mo, Yu-Qian Sun, Yi-Fei Cheng, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Yu Wang iD

European Journal of Haematology · 2026

DOI: 10.1111/ejh.70108 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Ning Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking Unive…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Beijing Research Ward Excellence Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Comparisons of safety and efficacy of Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) following complete remission (CR) achieved by Chimeric antigen receptor T (CAR‐T) cell therapy versus chemotherapy for B‐cell acute lymphoblastic leukemia (B‐ALL) have not been fully discussed.

Methods

We performed a comparison of transplant outcomes in 443 consecutive B‐ALL patients who received allo‐HSCT after achieving CR with CAR‐T therapy ( n = 50) or with chemotherapy ( n = 393). The median follow‐up time was 30 months (range: 1–62 months).

Results

The CAR‐T group had a lower incidence of chronic graft‐versus‐host disease (30.9% vs. 44.0%, p = 0.020). We also found that the incidence of veno‐occlusive disease was higher in the CAR‐T group compared to the chemotherapy group (4% vs. 0.5%; p = 0.003). The study revealed that both the CAR‐T and chemotherapy groups exhibited comparable overall survival (90.9% vs. 94.6%, p = 0.158) and relapse incidences (9.1% vs. 8.4%, p = 0.513). However, incidences of non‐relapse mortality after transplantation were higher in the CAR‐T group (10.9% vs. 4.3%, p = 0.016), and leukemia‐free survival was lower in the CAR‐T group compared to the chemotherapy group (80.0% vs. 86.8%, p = 0.040).

Conclusions

Our data indicate that, in B‐ALL patients, most treatment‐related complications and survival were comparable between CAR T‐cell therapy and chemotherapy followed by allo‐HSCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationImmunotherapy, AdoptiveReceptors, Chimeric AntigenPrecursor B-Cell Lymphoblastic Leukemia-LymphomaHumansFemaleMaleAdultAdolescentTransplantation, HomologousChildMiddle AgedChild, PreschoolYoung AdultTreatment OutcomeGraft vs Host DiseaseBridge TherapyCombined Modality TherapyRemission Induction

Stichwörter der Autor:innen

B‐cell acute lymphoblastic leukemiaallogeneic hematopoietic stem cell transplantationchemotherapychimeric antigen receptor T‐cell therapyoutcomestreatment‐related complications

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Peking University People's Hospital, Peking University Institut…
  • Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
  • State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China.

ORCID-Profile: Yu Wang

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Beijing Research Ward Excellence Program
  • Major Program of the National Natural Science Foundation of China
  • Beijing Municipal Science & Technology Commission
  • Peking University Medicine Fund for world's leading discipline or discipline cluster development
  • Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park

Zitieren

APA

Wu, N., Kong, J., Lv, M., Mo, X. D., Sun, Y. Q., Cheng, Y. F., Xu, L. P., Zhang, X. H., Huang, X. J., & Wang, Y. (2026). Bridging With Chimeric Antigen Receptor T‐Cell Therapy or Chemotherapy to Allo‐ HSCT in B‐ ALL : A Comparison of Treatment Complications and Survival. European Journal of Haematology. https://doi.org/10.1111/ejh.70108

Vancouver

Wu N, Kong J, Lv M, Mo XD, Sun YQ, Cheng YF, et al. Bridging With Chimeric Antigen Receptor T‐Cell Therapy or Chemotherapy to Allo‐ HSCT in B‐ ALL : A Comparison of Treatment Complications and Survival. European Journal of Haematology. 2026. doi:10.1111/ejh.70108

BibTeX
@article{Wu2026,
  author = {Wu, Ning and Kong, Jun and Lv, Meng and Mo, Xiao-Dong and Sun, Yu-Qian and Cheng, Yi-Fei and Xu, Lan-Ping and Zhang, Xiao-Hui and Huang, Xiao-Jun and Wang, Yu},
  title = {Bridging With Chimeric Antigen Receptor T‐Cell Therapy or Chemotherapy to Allo‐ HSCT in B‐ ALL : A Comparison of Treatment Complications and Survival},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70108}
}
Kostenlos starten →